Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An orally active selenium-based antihypertensive agent with restricted CNS permeability

S W May1, L Wang, M M Gill-Woznichak

  • 1School of Chemistry and Biochemistry, Georgia Institute of Technology and School of Pharmacy, Mercer University, Atlanta, Georgia 30332-0400, USA.

The Journal of Pharmacology and Experimental Therapeutics
|November 14, 1997
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelial nitric oxide synthase is a site of superoxide synthesis in endothelial cells treated with glyceryl trinitrate.

British journal of pharmacology·2000
Same author

Effects of NO donors and synthase agonists on endothelial cell uptake of L-Arg and superoxide production.

American journal of physiology. Cell physiology·2000
Same author

Antiinflammatory and analgesic activity of an inhibitor of neuropeptide amidation.

The Journal of pharmacology and experimental therapeutics·1997
Same author

Calcium bioavailability from bovine milk and dairy products in premenopausal women using intrinsic and extrinsic labeling techniques.

The Journal of nutrition·1996
Same author

Pyoderma gangrenosum in a patient with cryoglobulinemia and hepatitis C successfully treated with interferon alfa.

Journal of the American Academy of Dermatology·1996
Same author

Cutaneous manifestations and consequences of smoking.

Journal of the American Academy of Dermatology·1996

This study introduces the first oral selenium-based antihypertensive drug, demonstrating limited central nervous system (CNS) penetration. This novel agent shows promise for treating chronic diseases like hypertension.

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Neuroscience

Background:

  • Selenium biochemistry and pharmacology are areas of significant research interest.
  • Phenylaminoalkyl selenides exhibit unique redox chemistry impacting catecholamine metabolism.
  • Understanding selenium compound pharmacokinetics is crucial for drug development.

Purpose of the Study:

  • To report the first orally active, selenium-based antihypertensive agent.
  • To demonstrate restricted central nervous system (CNS) permeability of a novel selenium compound.
  • To evaluate the pharmacokinetic and behavioral effects of selenium-based antihypertensives.

Main Methods:

  • Inductively coupled plasma/mass spectroscopy (ICP/MS) for pharmacokinetic analysis.
  • Operant behavioral analysis to assess CNS effects.

Related Experiment Videos

  • Two-compartment pharmacokinetic modeling for data analysis.

    • Main Results:

    • The novel compound, 4-hydroxy-alpha-methyl-phenyl-2-aminoethyl selenide, demonstrated oral antihypertensive activity.
    • ICP/MS and behavioral studies confirmed restricted CNS permeability.
    • Pharmacokinetic analysis revealed rapid initial clearance and a short beta-elimination half-life.

    Conclusions:

    • The developed selenium compound is the first orally active agent with restricted CNS permeability for hypertension treatment.
    • This agent possesses desirable properties for managing chronic diseases.
    • Further research into selenium-based agents for hypertension is warranted.